Hypertension is common, affecting approximately 73 million Americans, with an additional 70 million considered to have prehypertension. 1 Serious sequelae of hypertension include stroke, heart failure, ischemic heart disease, and chronic renal failure.
Thiazide diuretics, β-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and calcium-channel blockers are considered appropriate first-line treatment for hypertension in the United States, 2 although there is recent debate about the first-line role of diuretics and β-blockers due to their adverse metabolic effects (AMEs). 3, 4 Despite availability of many effective agents, only about 40% of treated hypertensives have their blood pressure (BP) controlled. 1, 5 Variable drug efficacy may contribute, in part, to poor BP control because numerous studies have shown that any given drug is effective in only 40% to 60% of patients. 6 Initial therapy is often selected empirically, and BP responses to monotherapy vary widely within ethnic and gender subgroups. The low response rates to any particular antihypertensive drug suggest the current approach to therapy selection and hypertension management is not optimal. The Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study seeks to address whether genetic predictors of BP lowering in response to a thiazide diuretic, a β-blocker, or their combination can be identified. A secondary objective is to determine whether genetic predictors of AMEs to each monotherapy or combination therapy can be identified. The variable nature of these responses, previous studies suggesting genetic associations with BP responses, and the heritability of high BP, glucose, and lipids all lend evidence to the hypothesis that antihypertensive and adverse metabolic responses to thiazides and β-blockers may be under some genetic control. Information gained from this study may help individualize selection of antihypertensives in patients with uncomplicated essential hypertension.
Rationale for PEAR study design
The PEAR study is funded as part of the National Institutes of Health (NIH) Pharmacogenetics Research Network (http://www.pharmgkb.org/network/ pharmacogenetics_research_network.jsp) to investigate potential genetic contributors to antihypertensive and AME responses to thiazide diuretics and β-blockers, using both a candidate gene and genome-wide association approach. This broad approach will allow investigation of the contributions from multiple different genes to drug response variability.
Many previous hypertension pharmacogenetic studies have limited analyses to office (ie, clinic) measures of BP response, but PEAR will incorporate both home and 24-hour ambulatory measures as well as office measures of BP response. Evidence suggests office BP is not the optimal BP phenotype for assessing genetic predictors of drug response. Specifically, both ambulatory and home BP have been shown to be superior to office BP in predicting long-term outcomes. 7, 8 Reproducibility for ambulatory and home BP is also better than for office BP. 9 In addition, we and others have shown a relatively poor correlation between office BP and either ambulatory BP (ABP) or home BP, but good correlations between ambulatory BP and home BP. [10] [11] [12] Finally, office BP is associated with a placebo effect, whereas ambulatory and home BPs are not. 13, 14 Therefore, the data suggest the most appropriate BP phenotypes are home and ABPs rather than office BP, and these will be the primary focus in PEAR.
The PEAR study will also address genetic associations with monotherapy and combination therapy in hypertension. Although information on the genetic predictors of BP response in the untreated patient is important, it is increasingly clear that a large percentage of patients will require N1 drug for BP control. It is therefore important to understand whether associations documented between genetic polymorphisms and response to monotherapy are preserved when the drug of interest is added to existing antihypertensive therapy and the PEAR design will allow for such assessments.
Despite their widespread use for hypertension, thiazides and β-blockers are associated with AMEs that are the cause of increasing concern in the clinical community. Specifically, these AMEs have led some to suggest neither drug class should be considered first-line therapy for uncomplicated hypertension. 3, 4 However, only a relatively small portion of the population experiences these AMEs. If genetic contributors to AMEs could be identified a priori, clinicians could choose to avoid these drugs in at-risk individuals. Despite the increasing focus on the AMEs of these drugs, data on genetic contributions to these effects are limited. In PEAR, these adverse metabolic response phenotypes will be assessed at the same time as BP responses, through determination of specific laboratory measures collected under fasting conditions. The primary end point for AMEs on glucose is the homeostatic model assessment, which incorporates fasting glucose and insulin levels to arrive at a measure of insulin sensitivity and β-cell function. Estimates of insulin resistance/sensitivity and pancreatic β-cell function, in diabetics and nondiabetics, by homeostatic model assessment have been well correlated with invasive "gold standard" methods like euglycemic or hyperglycemic clamping, minimal modeling, and others. 15 Change in triglycerides is our primary end point for lipid AMEs because sustained effects on triglycerides have been noted for β-blockers and thiazides, and elevated triglycerides are a determinant of metabolic syndrome, and a modifiable risk factor for coronary disease.
Atenolol and hyrochlorothiazide (HCTZ) were specifically selected for several reasons. They are the most commonly used antihypertensive drugs within their respective classes, with each drug prescribed N40 million times annually in the United States. Given their widespread use, resulting data would potentially be of high clinical value. Both drugs are also dosed once daily, which is documented to enhance adherence to therapy. 16 Finally, these drugs were chosen because of the relative lack of genetic influence on their pharmacokinetics, thus reducing confounding effects of pharmacokinetic variability. Specifically, both drugs are primarily eliminated by the kidneys and thus not influenced by genetic variation in drug-metabolizing enzymes, as are other drugs, including other β-blockers. This trial was proposed and initiated before the publication of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) trial data, 17 which has called into question the role of atenolol in hypertension management. Nonetheless, atenolol remains a widely used drug, and even if its use falls out of favor over the next decade, pharmacogenetic data on a variety of β-blockers suggest findings are consistent across the drug class. Thus, pharmacogenetic findings with atenolol from this study are likely to be applicable to other β-blockers used in hypertension.
PEAR study design

Study population
Males or females (N = 800) with mild to moderate essential hypertension, of any race or ethnicity, between the ages of 17 and 65 are being recruited to participate. Subjects are being enrolled at the University of Florida (Gainesville, FL), Emory University (Atlanta, GA), and the Mayo Clinic (Rochester, MN). In Gainesville, subjects are recruited from Department of Community Health and Family Medicine clinics, which are primary care clinics. In Atlanta, subjects are recruited through outpatient medical clinics at Grady Memorial Hospital, the Hypertension and Renal Diseases Research Center at Emory University, advertisements in public media, and through mailings to registered voters. In Rochester, subjects are recruited from a list of all residents of Olmsted County seen by a health care provider in the previous 3 years who have a diagnosis of hypertension. Thus, study participants at all 3 sites are drawn almost exclusively from the primary care setting. The study has been approved the institutional review boards at each institution, and all subjects provide informed, written consent before being screened for participation. Information collected on participants' race and ethnicity are self-defined and collected according to the guidelines set forth by the NIH.
Potential subjects are those with newly diagnosed, untreated, or known hypertension currently treated with 1 or 2 antihypertensive drugs. Inclusion and exclusion criteria are shown in Table I . Subjects not meeting any exclusion criteria are further screened for BP inclusion, based on untreated home and office BP. Subjects undergo training by research personnel on the use of the home BP monitor and are provided a monitor and appropriately sized cuff to take home. Those currently treated have their antihypertensive drug therapy tapered (as necessary) and discontinued, with a minimum antihypertensive-free period of 18 days and a preferred washout period of 4 to 6 weeks.
BP inclusion
During the entire study, participants are requested to take their home BP twice daily, on rising from bed and before retiring. After at least 18 antihypertensive drug-free days, they are screened for inclusion based on both home and office BP data. The BP inclusion requires an average (previous week) seated home diastolic BP (DBP) N85 mm Hg and an average seated (N5 minutes) office DBP N90 mm Hg. Subjects are excluded if by either method DBP is N110 mm Hg or systolic BP (SBP) is N180 mm Hg.
Study protocol
The study protocol (Figure 1 ) is initiated in subjects who meet all eligibility criteria for the study.
Baseline studies
Data collected at various study visits are shown in Table II . Subjects meeting eligibility criteria undergo baseline collection of home and 24-hour ABP data. For ABP monitoring, subjects report to clinic for ABP monitor placement then return to usual daily activities. They return to clinic 24 hours after ABP placement. Biological samples are collected in the fasting state and include plasma, serum, buffy coat, and a spot urine (unpreserved and preserved with ascorbic acid) in sufficient quantities to meet the study aims and to support future research. Laboratory parameters determined in all subjects (from plasma or serum, as appropriate) for primary study analyses include glucose, insulin, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, sodium, potassium, magnesium, creatinine, and uric acid. There are no primary planned analyses for urine samples; they are collected to facilitate future research.
Treatment phase
After completion of baseline studies, subjects are randomized to hydrochlorothiazide 12.5 mg daily or atenolol 50 mg daily in an unblinded fashion. Given that all study phenotypes are objective in nature and efficacy of the study drugs is well established, it was not felt that blinding was needed. Throughout the protocol, those with an average home or office SBP N120 mm Hg or DBP N70 mm Hg continue to move through the titration protocol, whereas those with BPs ≤120/70 mm Hg hold at their current treatment step. Subjects return with their home BP data after 3 weeks on the initial dose, and based on BP noted above, they undergo dose titration. They continue on this dose for a minimum of 6 additional weeks, after which they undergo studies to assess their response to the first study drug (response assessment 1). Those with BP ≤120/70 mm Hg proceed directly to response assessment 1 after at least 6 weeks on the initial dose ( Figure 1) . Response assessment studies are identical to baseline studies (Table II) . In addition, samples are collected at this visit for creation of Epstein-Barr virus transformed lymphocytes to create a permanent source of DNA and support future tissue based studies. After completion of response assessment 1, most subjects (ie, those with BP N120/70 mm Hg) have the alternate drug added and continue through the protocol as in the first phase, after which they repeat response assessment studies.
Safety procedures
Data on adverse effects are collected at every study visit and monitored to detect unexpected adverse events. Numerous safety procedures are in place to insure patient safety, particularly during the antihypertensive drug washout period. First, many of the exclusion criteria are designed to exclude those at moderate to high risk. In addition, subjects are encouraged to conduct daily home BP monitoring and to report immediately any readings with SBP N180 mm Hg or DBP N110 mm Hg. Subjects are withdrawn for any average home BP from the previous week or an office BP of SBP N180 mm Hg or DBP N110 mm Hg and restarted on their previous antihypertensive regimen or referred for care. The protocol also requires moving backward by 1 treatment step for symptomatic hypotension (regardless of BP) or for any SBP b100 mm Hg (regardless of symptoms). Any subject with heart rate (HR) b55 beat/min is precluded from receiving a higher atenolol dose, and in the case of symptomatic bradycardia, the atenolol dose is decreased or the drug is stopped.
Electrolytes are also carefully monitored, with clinical determination at a local laboratory of serum potassium at each visit while a subject is taking hydrochlorothiazide. Study physicians can elect to replace potassium at any value, with protocol mandated prescription of oral potassium chloride 40 mEq daily for any potassium b3.2 mEq/L. Serum potassium is rechecked every 3 to 4 weeks, and potassium chloride doses increased as needed until potassium is normalized. The PEAR study protocol.
Finally, PEAR has an external Data Safety and Monitoring Board, charged with monitoring safety of the study protocol, along with data quality.
Methods for BP assessment
Home BP assessment
Home BP is determined using the Microlife model 3AC1-PC home BP monitor (Minneapolis, MN), a device that has met the standards of the British Society of Hypertension and the Association for the Advancement of Medical Instrumentation. 18 All BP measurements are taken in triplicate mode, and the monitor averages the values. SBP, DBP, HR, and a date/time stamp are recorded. The BP monitor stores up to 99 measurements, from which data are downloaded via a computer interface. Subjects bring their home BP monitor to each clinic visit, and the study coordinator downloads the data to the computer, using these data to make protocol-driven decisions. In order for the home BP data to be accepted, there must be at least 5 morning and 5 evening readings during the previous 7 days. If insufficient home BP data are recorded, study participants are asked to return when they have sufficient home BP data. Before giving the participant the home BP monitor on their first visit, study coordinators document the accuracy of the home BP monitor against manual measurement, with 6 measurements by home monitor and manual methods. If the 2 methods differ by N8 mm Hg, a different home BP monitor is used.
Office BP assessment
All office BPs are taken using the home BP monitor assigned to the subject, such that any differences in home and office BP can be attributed to the setting and not the device used to take the BP. Office BP is taken in triplicate, after the subject has been seated for at least 5 minutes.
Ambulatory BP assessment
Ambulatory BP monitoring is performed using Spacelabs (Redmond, WA) model 90207, which has also met the standards for accuracy of the British Society of Hypertension and the Association for the Advancement of Medical Instrumentation. 18 The ABP monitor is preprogramed to randomly record BPs 4 times hourly during the daytime or active hours (eg, 0600 to 2200) and twice hourly during the nighttime or inactive hours (eg, 2200 to 0600). Times are adjusted appropriately for night workers. A validation procedure similar to the one described for the home BP monitor is applied to the ABP monitor.
Assessing adherence to therapy
To aid adherence and its monitoring, study medication is provided in blister packs, labeled with the day of the week. This serves as a "pillbox" equivalent and aids the patient in remembering whether they took their dose. Participants are instructed to bring their blister packs to study visits, from which a pill count is made. This includes assessment of total number of doses missed and the specific day on which doses are missed in the week before the study visit. Those with poor adherence are provided counseling on improved adherence strategies. Availability of detailed adherence data in the week before the study visit (during which home BP data are being captured) allows for exclusion of subjects with poor adherence (eg, b70%) and/or inclusion of adherence data in analysis models.
Planned genetic analyses
Both candidate gene and genome-wide association analyses will be undertaken. Candidate gene genotyping will be accomplished using the Vascular Disease 50,000 SNP Array (Illumina, San Diego, CA) chip, 19 a cardiovascular gene custom array that includes approximately 2,200 cardiovascular and metabolic-related genes, covered through assay of approximately 50,000 single nucleotide polymorphisms (SNPs) using a tag SNP approach. Genome-wide association genotyping will be accomplished using the Affymetrix 6.0 Array (Affymetrix, Santa Clara, CA). At study inception, we proposed to study 70 biological candidate genes (Table III) , along with study of 20,000 genome-spanning putative functional SNPs. Although the arrays described above will provide substantially more data than originally envisioned, our initial analyses will still focus on the original 70 candidate genes and the 20,000 putative functional SNPs.
Given that we have a large number of European Americans and African Americans, this presents certain potential challenges in the analyses. We will deal with these in several ways, including initial analyses that consider the 2 groups separately. If the associations are similar, then the groups will be combined, and the analyses will control for the self-defined race, along with estimates of ancestry, which will be determined based on ancestry informative markers that are contained on both arrays being utilized. More detailed information on this issue, and all other analysis issues, will be contained in the individual manuscripts reporting genetic associations.
Data and sample sharing
Based on conditions of the NIH award, genotype and phenotype data will be deposited upon publication of the data in a database accessible to scientists. Primary phenotype and genotype data deposits will be made to PharmGKB (www.pharmgkb.org). High-throughput genotype data sets will be deposited in dbGaP (http://www. ncbi.nlm.nih.gov/sites/entrez?db=gap) with appropriate links and meta-data in PharmGKB. In addition, there is a sample sharing plan for biological samples, including DNA, cell lines, plasma, serum, and urine, under which investigators may submit an ancillary proposal to the PEAR steering committee to conduct analyses in collaboration with PEAR investigators.
Funding and trial registration
PEAR is funded by the NIH (U01 GM074492). It is registered at ClinicalTrials.gov, #NCT00246519; URL: http://clinicaltrials.gov/ct2/show/NCT00246519. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents.
Results
Baseline demographic characteristics of the first 418 subjects to complete the PEAR protocol are shown in Table IV . These data reveal the subjects are, on average, middle aged and obese (body mass index = 31). Epithelial sodium channel displays the progression of the first 1,000 subjects enrolled in PEAR. It shows that a high percentage of subjects (N40%) cannot be randomized into the trial, with failure to meet inclusion/exclusion criteria as the major reason. Before randomization, 3 (0.3%) subjects were excluded for an adverse event or safety concern, and in no case was the adverse event definitely attributed to study participation. After randomization 7 (1.3%) subjects were excluded from further participation either because their BP exceeded protocol safety limits or the patient was uncomfortable about their BP level. These data highlight the safety of the protocol. Based on pill counts, 83.4% and 86.6% of subjects were 100% adherent at the time of response assessment to monotherapy and combination therapy, respectively. Focusing on adherence in the 7 days before response assessments, 93.3% of subjects missed no doses, 4.8% missed 1 dose, and 1.9% missed 2 or more doses. The dose immediately before the response assessment visit was missed by 2.2% of subjects.
Discussion
We describe the study design for the PEAR study, which is funded as part of the NIH Pharmacogenetics Research Network. The primary objective of PEAR is to evaluate the genetic determinants of the BP and adverse metabolic responses to β-blockers and thiazide diuretics, with the long-term goal of potentially being able to utilize such information to help guide selection of the most appropriate antihypertensive drug for an individual patient.
The study population consists of uncomplicated hypertensive subjects, where uncomplicated means they have no concomitant diseases that influence their initial antihypertensive therapy. Empiric therapy of hypertension is primarily with the uncomplicated hypertensive patient; thus, this is the setting where pharmacogenetics may be of greatest clinical value. Other reasons for the focus on a sample of uncomplicated hypertensives is that it is a group with relatively fewer confounding variables (eg, concomitant disease states) and the group for whom temporary washout of antihypertensive therapy is most likely to be safe. The data to date support this is a group in whom antihypertensive drugs can be safely withdrawn for several weeks.
In summery, PEAR will be unique as a hypertension pharmacogenetics study due to its focus not only on genetic associations of BP response but also on adverse metabolic responses to these drugs. Progression of first 1,000 subjects enrolled in PEAR.
